MicrobeWorld App

appsquarebannerad200x200

Join MicrobeWorld

Subscribe via Email

subscribe

Microbes After Hours

MW-Site-Banner-200x200

Click for more "Microbes After Hours" videos

Featured Image

Featured Video

Crowdsourced Microbes Heading to Station

Supporters

ASM House 200X200

ICAAC 2013 - High Dose Therapy for Influenza Drug

Critically ill patients  with the pandemic H1N1 influenza who received triple the standard dose of the influenza drug oseltamivir were 7 times more likely to completely clear the virus from their system in 5 days than those who received the standard dose. This discussion will address the healthcare implications of these findings, including a rationale for high dose therapy of sensitive strains of influenza.

 

Comments (1)

  1. If benefit of the standard dose is minimal, near 0, then 7 times 0 is near 0 too. The BMJ meta-study showed problematic side-effects and a small gain for Tamiflu. Here no side-effects, large gain? Small study, big conclusions? Disclosure: Kumar has a research relationship with Roche Pharmaceuticals. http://www.healio.com/infectious-disease/eacs-2013-resource-center/idn0913kumar_10_3928_1081_597x_20130901_12_1310881 Given two experimental timelines, if you can choose the moment of comparison later at will, there is great chance that there is a cutoff (here after 5 days) when one of the experiments is much better than the other. That would be bad statistics.

Collections (0)

American Society for Microbiology
2012 1752 N Street, N.W. • Washington, DC 20036-2904 • (202) 737-3600
American Society For Microbiology © 2014   |   Privacy Policy   |   Terms of Use